Dr. Gaynor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Lilly Corporate Ctr
Indianapolis, IN 46285Phone+1 317-651-5134
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1980
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1975 - 1978
University of Texas Southwestern Medical SchoolClass of 1975
Certifications & Licensure
CA State Medical License 1978 - Present
IN State Medical License 2002 - 2025
TX State Medical License 1975 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1988
Publications & Presentations
PubMed
- 9 citationsDefining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction.Jennifer G Abelin, Dewi Harjanto, Matthew Malloy, Prerna Suri, Tyler Colson
Immunity. 2021-02-09 - 32 citationsCombined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.Asaf Poran, Julian Scherer, Meghan E. Bushway, Rana H. Besada, Kristen N. Balogh
Cell Reports. Medicine. 2020-11-17 - 372 citationsA Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Patrick A. Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing
Cell. 2020-10-15
Press Mentions
Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01December 18th, 2019- Neon Therapeutics Announces New Strategic Focus on Novel T Cell ProgramsNovember 20th, 2019
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific NeoantigensSeptember 5th, 2019- Join now to see all
Grant Support
- Inhibition Of NFKB Pathway On Growth Of Colon CarcinomaNational Cancer Institute2001–2002
- Mechanisms Regulating HIV-1 Gene ExpressionNational Institute Of Allergy And Infectious Diseases2001
- Cellular Proteins Involved In HIV1 TAR RNA FunctionNational Institute Of Allergy And Infectious Diseases1999–2001
- Properties Of The HTLV I Tax ProteinNational Cancer Institute1998–2000
- TAT Associated Kinase Regulation Of HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1997–2000
- Novel Treatment Of Brain TumorsNational Cancer Institute1997–2000
- HIV 1 LTR Regulatory ElementsNational Institute Of Allergy And Infectious Diseases1995–1999
- Cellular Proteins Involved In HIV 1 TAR RNA FunctionNational Institute Of Allergy And Infectious Diseases1994–1998
- Properties To The HTLV I Tax ProteinNational Cancer Institute1997
- Transdominant TAT Mutants Inhibit HIV Gene ExpressionNational Institute Of General Medical Sciences1996
- Adenovirus E1A Protein Interaction With Cellular FactorsNational Cancer Institute1993–1996
- Regulation Of HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1991–1994
- Cellular And Viral Proteins And HIV RegulationNational Institute Of Allergy And Infectious Diseases1991–1993
- Transcriptional Regulation By The Adenovirus EIA ProteinNational Cancer Institute1991–1992
- Transcriptional Regulation By The Adenovirus E1A ProteinNational Cancer Institute1988–1991
- Regulation Of HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1990
- Cellular And Viral Proteins And HIV RegulationNational Institute Of Allergy And Infectious Diseases1989–1990
- Cellular Proteins Which Regulate HIV Gene ExpressionNational Institute Of Allergy And Infectious Diseases1987–1989
- Transforming Functions Of Adenovirus EIA ProteinsNational Cancer Institute1985–1986
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
